Philips Launches HealthSuite Clinical Trial Accelerator to Help Life Science Organizations Run More Flexible, Patient-Centric Clinical Trials

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources, providing actionable insights for better, faster decision-making.

Philips HealthSuite is an integrated, modular set of standards-based capabilities that support the development of digital propositions across the health continuum, encompassing HIPAA compliant, secure cloud capabilities. Clinical Trial Accelerator enables patient-centric trials at home, managing the collection of data while providing the security and compliance expected from both patients and life science organizations.

Life science organizations face continued pressure to run more efficient, cost-effective clinical trials. Empowering patients and making it easier for them to stay connected and contribute to a trial can have a significant impact on compliance rates and overall success. At the same time, collecting data and identifying actionable insights while ensuring the security and compliance of patient information is key. Clinical Trial Accelerator is designed to address these challenges, helping life science organizations reach their goals faster and supporting greater flexibility in trial design.

"Philips HealthSuite already provides cloud-based services and tools to a wide array of healthcare organizations, and with Clinical Trial Accelerator we have created a tailored set of capabilities to support life science organizations," said Dale Wiggins, General Manager for the HealthSuite digital platform at Philips. "Our innovative, flexible cloud platform leverages our global healthcare capabilities and is supported by our compliance, security and interoperability expertise."

Tailored capabilities to accelerate clinical trials

Other HealthSuite capabilities include an AI Analytics Workbench for enhanced decision making and standards-based interoperability for Digital Imaging and Communication in Medicine (DICOM) data, as well as the HealthSuite Clinical Data Lake, a new scalable micro-service that acts as a centralized big data repository for high-volume clinical data collection studies and includes controls to curate and manage data in a manner that addresses regulatory requirements.

These HealthSuite capabilities offer companies cloud-based services and technical tools that meet privacy, security and regulatory requirements that they can use to develop and run a new generation of connected healthcare applications. Unlike other digital platforms, HealthSuite is purpose-built to solve the complex challenges of healthcare, featuring capabilities to manage device data, collect personal and health data, store and share data securely, analyze data, build and deploy AI models, and create solutions on the cloud.

In addition, these HealthSuite capabilities power a wide range of both Philips and 3rd party connected healthcare applications in areas including image-guided therapy, sleep and respiratory care, ophthalmology, telehealth and self-medication. For 3rd party collaborations, Philips is the provider of the relevant cloud-based healthcare IT infrastructure and is not involved in the commercialization of the products and services of these companies.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries.

Most Popular Now

First Virtual DMEA to Open with a Wide R…

16 - 18 June 2020, Berlin, Germany. Under the heading 'DMEA sparks' and taking place for the first time, this year's DMEA is an entirely virtual event. From 16 to 18...

Philips Launches HealthSuite Clinical Tr…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to...

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...

WiFi SPARK Works with Visionable to Conn…

Seven NHS Trusts are using technology developed by WiFi SPARK in response to an urgent request from leading NHS Trusts to find a way to connect hospital patients with their...

Digital Contact Tracing for COVID-19: An…

An article in CMAJ (Canadian Medical Association Journal) analyzes the strengths and limitations of digital contact tracing for people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to help...